Endometrial Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Effects of adjunctive metformin on recurrence-free survival and reproductive outcomes following progestin-based fertility-sparing treatment for endometrial neoplasia: Results from the FELICIA trial, a prospective, randomized, phase IIb trial with blinded central adjudication.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
This multicenter, open-label, randomized, phase IIb trial evaluated whether adding metformin to medroxyprogesterone acetate (MPA) improves outcomes in women with atypical endometrial hyperplasia or presumed stage IA grade 1 endometrioid carcinoma undergoing fertility-sparing treatment. A total of 154 women were randomized 1:1:1 to MPA alone, MPA plus metformin 750 mg/day, or MPA plus metformin 1500 mg/day, with blinded central adjudication of remission and recurrence. The 3-year recurrence-free survival rates were 44.7% with MPA alone and 44.5% with pooled metformin groups (P=0.825), while remission rates were 54.0%, 58.8%, and 50.9%, respectively. The authors concluded that adding metformin did not improve recurrence-free survival or remission rates, suggesting limited benefit in this fertility-sparing setting.
10.1016/j.ygyno.2026.10.004
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
CANCER-AM CANCER SOC · Q1 JOURNAL - RANK #68/326
This study reports results from NRG-GY012, a phase 2 trial evaluating olaparib, cediranib, and their combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer. Ninety-six baseline plasma samples were analyzed for circulating protein biomarkers to assess predictive and prognostic associations with progression-free survival and overall survival. The primary analysis focused on IL-6, which did not validate at the prespecified 2.9 pg/mL cut point but was associated with overall survival at a median cut point of 4.2 pg/mL, with higher IL-6 levels linked to longer OS benefit in cediranib arms. Secondary analyses identified osteopontin and placental growth factor as potential predictive biomarkers, and multiple prognostic markers were also identified, warranting further evaluation.
10.1002/cncr.70649
Oct 05 – Oct 12, 2026
Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This multicentre, single-arm, phase 2 trial evaluated neoadjuvant niraparib monotherapy in 67 patients with treatment-naïve, HRD-positive, advanced high-grade serous or endometrioid ovarian cancer initially unsuitable for primary debulking surgery. Patients received oral niraparib for two 28-day cycles, with co-primary endpoints of objective response rate and R0 resection rate after interval debulking surgery. Among 48 response-evaluable patients, the objective response rate was 63% (95% CI 47-76), and among 40 operated patients, the R0 resection rate was 80% (95% CI 64-91). The authors conclude that neoadjuvant niraparib showed anti-tumour activity and enabled R0 resection, but requires randomised validation against standard neoadjuvant chemotherapy.
10.1016/S1470-2045(26)00387-6
Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
The CLEAR-EC multicenter single-arm phase II trial evaluated cadonilimab plus lenvatinib as second-line or later therapy in advanced endometrial cancer after platinum-based chemotherapy. Thirty-two patients were enrolled, including three in a safety run-in, with the primary endpoint of objective response rate. The trial met its primary endpoint with an objective response rate of 40.6% (95% CI 23.7-59.4), disease control rate of 81.3% (95% CI 63.6-92.8), median progression-free survival of 13.8 months, and median overall survival not reached; grade ≥3 treatment-related adverse events occurred in 40.6%. The authors conclude that cadonilimab plus lenvatinib is active and has a manageable safety profile in this population.
10.1038/s41467-026-77467-3
E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort.
ECLINICALMEDICINE · Q1 JOURNAL - RANK #11/332
This global phase 1b/2 dose-expansion cohort evaluated E7386 plus lenvatinib in 30 patients with advanced endometrial cancer progressing after platinum-based chemotherapy and anti-PD-(L)1 immunotherapy. This single-arm, open-label trial administered E7386 120 mg twice daily plus lenvatinib 14 mg once daily (amended from 20 mg), with safety as the primary endpoint and ORR, duration of response, clinical benefit rate, and PFS as secondary endpoints. All patients experienced TEAEs (most commonly vomiting, 73.3%), with grade 3 TEAEs in 63.3% and no grade 4-5 events; confirmed responses occurred in 11 patients (one complete, ten partial) for an ORR of 36.7% overall and 57.1% in lenvatinib-naive patients. The authors conclude that E7386 plus lenvatinib shows promising antitumour activity with manageable safety in heavily pretreated advanced endometrial cancer.
10.1016/j.eclinm.2026.104206
Sep 28 – Oct 05, 2026
Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This phase 2 randomized clinical trial evaluated the efficacy of adding ribociclib to everolimus/letrozole in patients with recurrent endometrial cancer, randomizing participants to experimental (ribociclib combination) or control (everolimus/letrozole alone) arms, with progression-free survival as the primary endpoint. Among all-comers, no significant differences were observed in PFS (HR 0.78, 95% CI 0.4-1.4, p=0.38), OS (HR 0.8, 95% CI 0.4-1.5, p=0.46), ORR (44.1% vs 25.7%, p=0.11), or toxicity-related discontinuation (8.6% vs 11.4%, p=0.22). However, patients with prior endocrine therapy showed significantly higher ORR in the experimental arm (61.5% vs 0.0%, p<0.001), and within the experimental arm, CTNNB1 tumors were associated with improved PFS (HR 0.27, p=0.006) and OS (HR 0.24, p=0.004). The authors conclude that despite no survival benefit in all-comers, adding ribociclib may improve efficacy in prior endocrine therapy patients and CTNNB1 tumors may predict prolonged response.
10.1038/s41467-026-77049-3
Aug 17 – Aug 24, 2026
The optimal temperature of air-heated blankets for preventing intraoperative hypothermia in patients with gynecological tumor: a randomized controlled trial.
FRONT MED-LAUSANNE · Q1 JOURNAL - RANK #61/332
This randomized controlled trial aimed to determine the optimal temperature of air-heated blankets for preventing intraoperative hypothermia in patients undergoing radical resection for endometrial cancer. Following general anesthesia, patients were randomized to receive warming blankets set at 36°C, 38°C, or 40°C, with outcomes including core temperature, recovery times, and perioperative complications. The study found six cases of hypothermia in the 36°C group, while no hypothermia occurred in the 38°C and 40°C groups, with significant differences in hypothermia and shivering incidences; extubation and eye-opening times were shorter at 40°C than at 36°C. The authors concluded that 38°C is the optimal temperature and provided clinical guidance, with the trial registered under ChiCTR2400080803.
10.3389/fmed.2026.1835872